<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320134</url>
  </required_header>
  <id_info>
    <org_study_id>PoliclinicoCasilino1-2020</org_study_id>
    <nct_id>NCT04320134</nct_id>
  </id_info>
  <brief_title>cliNIcal sCEnarios and Pathophysiology of Atrial Fibrillation</brief_title>
  <acronym>NICE-AF</acronym>
  <official_title>CliNIcal SCEnarios and Pathophysiological Features of Patients With Atrial Fibrillation: a Long Term Prospective Study (NICE-AF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Policlinico Casilino ASL RMB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Policlinico Casilino ASL RMB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia with prevalence
      and incidence continuously increasing worldwide. Current guidelines propose an etiological,
      symptom-based classification of the arrhythmia and mainly focused on its duration with
      consequent rhythm or rate-control strategies. Moreover, risk scores for atherothrombotic
      systemic or hemorrhagic events related to atrial fibrillation are principally based on
      patients cardiovascular history and risk factors.

      This approach do not consider relevant pathophysiological aspects that may play a pivotal
      role in triggering or perpetuating the arrhythmia, especially at its first occurrence. At
      this point, a crucial step would be deeply investigating AF clinical and pathophysiological
      features to guide a tailored diagnostical and therapeutic approach. Indeed, early recognition
      and proper characterization of triggers, substrates, autonomic system imbalance and
      modulating factors (drugs, electrolytes, etc) are of the utmost importance for AF care and
      management.

      Therefore, this large scale prospective observational study aims to evaluate clinical and
      pathophysiological features of patients with symptomatic and asymptomatic atrial fibrillation
      in different scenarios to understand possible distinctive characteristics warranting a
      personalized approach to the arrhythmia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Rate of Atrial Fibrillation recurrences</measure>
    <time_frame>5 years</time_frame>
    <description>frequency distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>5 years</time_frame>
    <description>frequency distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of thromboembolic events</measure>
    <time_frame>5 years</time_frame>
    <description>frequency distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of bleeding events</measure>
    <time_frame>5 years</time_frame>
    <description>frequency distribution of minor, major and fatal bleedings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participants socio-demographic characteristics</measure>
    <time_frame>baseline and 5 years</time_frame>
    <description>Frequency distribution: age, gender, race, occupation, life-style, diet, physical activity, alcohol consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with comorbidities</measure>
    <time_frame>baseline and 5 years</time_frame>
    <description>Frequency distribution: hypertension, heart failure, diabetes mellitus, kidney failure, dyslipidemia, lung diseases, thyroid disorders, gastrointestinal and liver disorders, hematological diseases, neoplasms, autoimmune disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with Heart diseases</measure>
    <time_frame>baseline and 5 years</time_frame>
    <description>frequency distribution: vascular diseases, valvular problems, cardiomyopathies, arrhythmias, family/genetic history of cardiovascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with Atrial Fibrillation secondary to triggers and/or autonomic system imbalance and/or modifiable factors</measure>
    <time_frame>baseline and 5 years</time_frame>
    <description>Frequency distribution of patients in which atrial fibrillation was clearly related to adrenergic tone imbalance and/or vagal tone imbalance and/or secondary to modifiable factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe imaging parameters (echocardiogram and cardiac magnetic resonance)</measure>
    <time_frame>baseline and 5 years</time_frame>
    <description>Left ventricle, right ventricle, right and left atrium and valves: morphologies, volumes, dimensions and function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of laboratory biomarkers</measure>
    <time_frame>baseline and 5 years</time_frame>
    <description>Complete Blood cell count with differential; Interleukin-1, Interleukin-6, High sensitivity C Reactive protein</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        In this prospective observational study we consider to enroll patients with diagnosis of
        Atrial Fibrillation (new onset, paroxysmal, persistent, long-persistent and permanent)
        admitted to our Hospital in the Emergency Room and/or Cardiology Department/Ambulatory Care
        Center.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with electrocardiographic diagnosis of Atrial Fibrillation (New Onset,
             Paroxysmal, Persistent, Long Standing Persistent and Permanent) admitted to the
             Emergency Room and/or Cardiology Department /ambulatory care center of our Hospital

          -  Age &gt;18 years old

          -  Patients who can give their written informed consent.

        Exclusion Criteria:

          -  Age &lt;18 years old

          -  Patients who cannot give their written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leonardo Calò</last_name>
    <phone>+390623188406</phone>
    <email>leonardocalo.doc@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonardo Calò</last_name>
    <phone>+390623188406</phone>
  </overall_contact_backup>
  <reference>
    <citation>Curtis AB, Gersh BJ, Corley SD, DiMarco JP, Domanski MJ, Geller N, Greene HL, Kellen JC, Mickel M, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG; AFFIRM Investigators. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005 Apr;149(4):645-9.</citation>
    <PMID>15990747</PMID>
  </reference>
  <reference>
    <citation>Siontis KC, Gersh BJ, Killian JM, Noseworthy PA, McCabe P, Weston SA, Roger VL, Chamberlain AM. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. Heart Rhythm. 2016 Jul;13(7):1418-24. doi: 10.1016/j.hrthm.2016.03.003. Epub 2016 Mar 4.</citation>
    <PMID>26961300</PMID>
  </reference>
  <reference>
    <citation>Heijman J, Guichard JB, Dobrev D, Nattel S. Translational Challenges in Atrial Fibrillation. Circ Res. 2018 Mar 2;122(5):752-773. doi: 10.1161/CIRCRESAHA.117.311081. Review.</citation>
    <PMID>29496798</PMID>
  </reference>
  <reference>
    <citation>Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC; RACE Investigators. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm. 2014 Jun;11(6):939-45. doi: 10.1016/j.hrthm.2014.03.016. Epub 2014 Mar 13.</citation>
    <PMID>24632222</PMID>
  </reference>
  <reference>
    <citation>Frykman V, Frick M, Jensen-Urstad M, Ostergren J, Rosenqvist M. Asymptomatic versus symptomatic persistent atrial fibrillation: clinical and noninvasive characteristics. J Intern Med. 2001 Nov;250(5):390-7.</citation>
    <PMID>11887973</PMID>
  </reference>
  <reference>
    <citation>Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, Noseworthy PA, Pack QR, Sanders P, Trulock KM; American Heart Association Electrocardiography and Arrhythmias Committee and Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Lifestyle and Cardiometabolic Health. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020 Apr 21;141(16):e750-e772. doi: 10.1161/CIR.0000000000000748. Epub 2020 Mar 9.</citation>
    <PMID>32148086</PMID>
  </reference>
  <reference>
    <citation>Slomski A. Alcohol Abstinence Lowers Atrial Fibrillation Recurrence Risk. JAMA. 2020 Feb 25;323(8):701. doi: 10.1001/jama.2020.1005.</citation>
    <PMID>32096848</PMID>
  </reference>
  <reference>
    <citation>Stiell IG, Sivilotti MLA, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, McRae AD, Rowe BH, Brison RJ, Thiruganasambandamoorthy V, Macle L, Borgundvaag B, Morris J, Mercier E, Clement CM, Brinkhurst J, Sheehan C, Brown E, Nemnom MJ, Wells GA, Perry JJ. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet. 2020 Feb 1;395(10221):339-349. doi: 10.1016/S0140-6736(19)32994-0.</citation>
    <PMID>32007169</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Policlinico Casilino ASL RMB</investigator_affiliation>
    <investigator_full_name>Leonardo Calò, MD</investigator_full_name>
    <investigator_title>Professor, FESC</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>pathophysiology</keyword>
  <keyword>triggers</keyword>
  <keyword>substrates</keyword>
  <keyword>autonomic system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

